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OBJECTIVES: Numerous studies have demonstrated that fasting serum glucose (FSG) levels and certain sin-
gle-nucleotide polymorphisms (SNPs) are related to an increased risk of colorectal cancer (CRC); however, 
their combined effects are still unclear. 
METHODS: Of a total of 144,527 men and women free of cancer at baseline, 317 developed CRC during 5.3 
years of follow-up. A case-cohort study (n=1,691) was used, consisting of participants with a DNA sample 
available. Three well-known SNPs (rs3802842, rs6983267, rs10795668) were genotyped. Hazard ratios (HR) 
and 95% confidence intervals (CI) of CRC, colon and rectal cancer were calculated, with the Cox proportion-
al hazard models.
RESULTS: The crude incidence rates per 100,000 person-years were 41.1 overall, 48.4 for men, and 29.3 for 
women. Among participants with dysglycemia, SNPs rs3802842 and rs6983267 were both associated with an 
increased risk of CRC (HR, 3.2; 95% CI, 1.9 to 5.5 and HR, 1.8; 95% CI, 1.1 to 3.1, respectively) and rectal 
cancer (HR, 3.4; 95% CI, 1.8 to 6.6 and HR, 3.3; 95% CI, 1.6 to 7.1, respectively). The interaction effect of dys-
glycemia and SNPs was positive, that is, resulted in an elevated risk of CRC, but was not statistically significant.
CONCLUSIONS: This study demonstrates that both high FSG and certain SNPs are major risk factors for 
CRC and rectal cancer but that they did not interact synergistically. The difference in effect size of the SNPs 
according to CRC subtype (i.e., colon or rectal cancer) and presence of dysglycemia merits further research. 
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers 
worldwide. In Korea, the standardized incidence of CRC has 
increased from 21.2/100,000 people in 1999 to 57.6/ 100,000 
people in 2012 [1]. A steady increase in the incidence of CRC 
is expected in the future, partly as a result of factors such as the 
increase in Western dietary patterns, the increase in diabetes [2], 
and interaction between these factors and genetic factors [3]. In 
particular, an association with several common single-nucleo-
tide polymorphisms (SNPs) has been reported, with high repli-
cability. The SNPs associated with CRC have been found to ac-
count for 4.3% of the variation in multiple adenoma risk, with 
three SNPs (rs3802842, rs6983267, rs10795668) explaining 
3.0% of the variation [3].
Although colonoscopy plus biopsy is the gold standard for 
CRC screening and diagnosis, more than half of all patients do 
not want to undergo this procedure because of the invasive na-
ture and intestinal discomfort of colonoscopy [4]. Compared to 
endoscopy, tests of serum biomarkers are more convenient and 
less invasive and can be better accepted as part of a routine 
physical examination [5], but the diagnostic value of most se-
rum CRC markers still remains poor for most patients [6]. 
Correspondence: Sun Ha Jee 
Department of Epidemiology and Health Promotion, Graduate School of 
Public Health, Yonsei University, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 
03722, Korea
Tel: +82-2-2228-1523, Fax: +82-2-365-5118, E-mail: jsunha@yuhs.ac
Received: Oct 19, 2015, Accepted: Jan 6, 2016, Published: Jan 6, 2016
This article is available from: http://e-epih.org/
 2016, Korean Society of Epidemiology
 This is an open-access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original 
work is properly cited.
2Epidemiology and Health  2016;38:e2016002
Although many epidemiologic studies of CRC have investi-
gated diabetes and genetics as risk factors, there has been a lim-
ited exploration of their combined effects, reflecting limitations 
posed by the study population size and the exposure data avail-
able in the studies carried out to date. Detecting synergism among 
common risk factors would have substantial public health and 
clinical relevance because it would identify some individuals 
who are at extremely high risk. It is well known that early dis-
covery of high-risk groups is beneficial in reducing CRC inci-
dence and mortality by enabling management of risk factors [7].
We have conducted a prospective cohort study of the causes 
of cancer in Koreans. Blood samples and information concern-
ing diabetes were available for all participants in this large co-
hort. Follow-up was accomplished through record linkage at 
the national level and was complete except for emigrants. Here, 
we describe the risk for CRC in relation to fasting serum glucose 
(FSG) and SNPs over 5.3 years of follow-up, during which there 
were 234 diagnoses of CRC among our cohort of 117,258.
MATERIALS AND METHODS 
Study subjects 
Participants for this study were drawn from a pool of 270,514 
individuals (153,372 men and 117,142 women) who had vol-
untarily undergone health examinations in 11 centers located 
in Seoul and Kyunggi provinces in Korea from 1994 to 2010, 
which were used as the baseline. Of these individuals, 159,844 
Figure 1. Flow chart describing sample size. KCPS-II. Korean Cancer Prevention Study-II; IRB, institutional review board; LB, limited amount 
of blood. 
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provided informed consent and were followed prospectively, 
forming the cohort of participants in the Korean Cancer Pre-
vention Study-II (KCPS-II). A full description of KCPS-II has 
been previously published [2]. Of the 159,844 participants, 
156,836 donated a blood specimen for genetic studies. Of the 
156,836 participants, 2,947 who reported having prevalent 
cancer, including prevalent CRC, were excluded. In addition, 
9,362 participants who had missing values for body mass index 
(BMI), fasting blood glucose, smoking status, alcohol drinking, 
and/or exercise were excluded. As of December 2012, 317 of 
these 144,527 participants had been diagnosed with CRC. For 
our case-cohort study, we selected a subcohort for genetic test-
ing, which constituted an about 1.3% random sample (n=1,834) 
of all 144,527 participants (Figure 1). The institutional review 
board of Yonsei University approved the study. 
Questionnaire and anthropometric measurements
Each participant was interviewed by using a structured ques-
tionnaire to collect the following details: smoking history (never 
smoked, ex-smoker, or current smoker), alcohol drinking (non-
drinker vs. consumer of any amount of alcohol on a regular 
basis), and regular exercise (yes or no). Participant’s height and 
weight were measured while the participants were wearing light 
clothing. BMI was calculated by dividing the weight (kg) by the 
square height (m2). Systolic and diastolic blood pressures were 
measured after a rest period of at least 15 minutes.
Blood collection and biochemical analyses
For clinical chemistry assays, serum (separated from periph-
eral venous blood) was obtained from each participant after a 
minimum fasting period of 12 hours and stored at -70°C until 
the time of analysis. Levels of FSG, total cholesterol, triglycer-
ide, low-density lipoprotein cholesterol, and high-density lipo-
protein cholesterol were measured by using a Cobas Integra 
800 (Roche Diagnostics, Rotkreuz, Switzerland) and a Hita-
chi-7600 analyzer (Hitachi, Tokyo, Japan).
Single-nucleotide polymorphisms genotyping
As genetic factors for the risk of CRC, three well-known SNPs 
(rs3802842 in the COLCA1 gene, rs6983267 in the CASC8 
gene, and rs10795668 in the LOC105376400 gene) were se-
lected from previous studies [3]. DNA samples were isolated 
from the peripheral blood of participants and genotyped at DNA 
Link Inc. (Seoul, Korea). The genotyping was performed using a 
SNP typing assay (Fluidigm, San Francisco, CA, USA) accord-
ing to the manufacturer’s instructions. The genomic DNA flank-
ing the SNPs of interest was amplified by polymerase chain re-
action (PCR) with the specific target amplification (STA) primer 
set and Qiagen 2X Mutiplex PCR Master Mix (Qiagen, Hilden, 
Germany) in a 5-µL reaction volume containing 60 ng of ge-
nomic DNA. The PCR reactions were carried out as follows: 15 
minutes at 95ºC hot start, and 14 cycles of 1) 95ºC for 15 sec-
onds, 2) 60ºC for 4 minutes. After amplification, the STA prod-
ucts were diluted 1:100 in DNA suspension buffer. A sample 
(2.5 µL) of each diluted STA product was added to a Sample 
Pre-Mix containing 3 µL of 2X Fast Probe Master Mix, 0.3 µL 
of the SNPtype 20X Sample Loading Reagent, 0.1 µL of the 
SNPtype Reagent, and 0.036 µL of the ROX Reference Dye 
(Cat. no. 12223-012; Invitrogen Ltd., Paisley, UK). After the As-
say Pre-Mix and the Sample Pre-Mix were loaded onto the 48.48 
Dynamic Array, the SNP typing assay reaction was carried out. 
Analysis was carried out using Fluidigm SNP Genotyping Anal-
ysis software (version 4.0.1; Fluidigm Corp., South San Francis-
co, CA, USA). Internal quality control measures were employed 
to ensure the accuracy of the data. A total of 1,691 individuals 
were genotyped via this platform. 
Diagnosis of colorectal cancer 
Data regarding the incidence of CRC were obtained from the 
records of the National Cancer Registry. All incidence of CRC 
was confirmed by histological cell type. According to the Inter-
national Classification of Diseases, 10th revision (ICD-10), 
Table 1. General characteristics of study participants: the Korean 
Cancer Prevention Study-II
Whole cohort 
(n=144,527)
Subcohort 
(n=1,834)
Age (yr) 41.2±10.3 40.7±9.9
BMI (kg/m2)1 23.6±3.2 23.5±3.1
FSG (mg/dL) 91.4±19.1 90.3±17.6
Total cholesterol (mg/dL) 189.2±33.8 189.2±40.8
Systolic blood pressure (mmHg) 117.9±14.4 117.5±14.5
Sex (female, %) 38.3 36.6
Conditions (%)
   Dysglycemia (FSG >110 mg/dL)
   Any alcohol use 
   Exercise 
   Family history2
8.6
74.1
58.5
2.4
6.8
75.5
60.6
2.5
Smoking status (%)
   Ex-smokers
   Current smokers
17.6
28.9
16.5
28.7
Genetic polymorphism
rs3802842 AA 35.4
AC 48.9
CC 15.7
rs6983267 GG 19.0
GT 48.5
TT 32.6
rs10795668 AA 11.8
AG 48.2
GG 39.9
BMI, body mass index; FSG, fasting serum glucose. 
1BMI=weight in kg divided by height in m2. 
2Family history of colorectal cancer.
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CRC was coded as C18-C20 [9]. Deaths from CRC were ascer-
tained from the cause of death listed on death certificates.
Statistical analysis
Person-years were calculated from the baseline enrollment to 
December 2012 or the date of CRC diagnosis, death, or loss to 
follow-up. Crude incidence rates (per 100,000 person-years) 
were calculated from the person-years and number of cases of 
CRC. Hazard ratios (HRs) were calculated by using the Cox 
proportional hazard model, after adjusting for age, sex, BMI, 
smoking status, alcohol consumption, and regular exercise. These 
analyses were used after the FSG levels were divided into four 
categories on the basis of cut-offs at 100 mg/dL, 110 mg/dL, 
and 126 mg/dL. A chi-square goodness-of-fit test was used to 
assess whether the SNPs were in Hardy-Weinberg equilibrium 
and to identify differences in genotype frequencies between 
CRC cases and controls. All statistical tests were two-sided, and 
statistical significance was determined as p<0.05. SAS version 
9.2 (SAS Institute Inc., Cary, NC, USA) was used for all analyses.
RESULTS
The basic characteristics of the participants (144,527 in the 
whole cohort and 1,834 in the subcohort) are summarized in 
Table 1 and Figure 1. A total of 317 participants were newly di-
agnosed with CRC among the 144,527 participants over 771,052 
total person-years (mean follow-up 5.3 years) through to De-
cember 2012. The crude incidence rates per 100,000 person-
years were 41.1 overall, 48.4 for men, and 29.3 for women. The 
population had a low BMI on average, with 39.5% of the men 
and 15.1% of the women at 25 kg/m2 or above and 3.5% of 
the men and 1.6% of the women above 30 kg/m2. Both smok-
ing and alcohol use were substantially more common in men 
than in women. 
Table 2 shows the age-adjusted rates and relative risks (RRs) 
of CRC in relation to FSG and the three common SNPs. Higher 
FSG was associated with an increased risk of CRC, particularly 
among subjects with impaired fasting glucose (IFG; 100 ≤FSG 
≤125 mg/dL). The findings were similar when we examined 
the relationship of FSG to CRC subgroup among the subjects 
with DNA data. Considering only those participants with DNA 
(SNP) data, we examined the potential relationships between 
genotypes and CRC risk. The RR for CRC for those with geno-
type AC or CC in SNP rs3802842 was 1.7 and 1.3 times high-
er, respectively, than for those with genotype AA. The RRs for 
colon cancer and rectal cancer were similar, with the same ge-
notypic pattern for SNP rs3802842. Also, those with genotype 
TT in SNP rs6983267 had an increased risk of rectal cancer 
(HR, 2.3; 95% CI, 1.3 to 3.9), but not colon cancer. The RR for 
colon cancer with genotype GG in SNP rs10795668 was signif-
icant (HR, 1.9; 95% CI, 0.9 to 3.9). 
Table 3 shows the age-adjusted and gender-adjusted combined 
effect of SNPs and dysglycemia on the risk of CRC. Among par-
ticipants with dysglycemia, both SNPs rs3802842 and rs6983267 
were associated with an increased risk of CRC (HR, 3.2; 95% 
CI, 1.9 to 5.5 and HR, 1.8; 95% CI, 1.1 to 3.1, respectively) 
and rectal cancer (HR, 3.4; 95% CI, 1.8 to 6.6 and HR, 3.3; 
Table 2. Risk factors for colorectal cancer incidence as analyzed by Cox proportional hazard models: the Korean Cancer Prevention Study-II
 
Whole cohort (n=144,527)
Subjects with DNA data (n=1,691), case-cohort design
Colorectal cancer Colon cancer Rectal cancer
Case Rate1 RR (95% CI) Case RR (95% CI) Case RR (95% CI) Case RR (95% CI)
Age (yr) 317 41.1 1.1 (1.1, 1.1) 221 1.1 (1.1, 1.1) 114 1.1 (1.1, 1.2) 107 1.1 (1.1, 1.1)
Gender Men
Women
230
  87
48.4
29.4
1.0 (reference)
0.7 (0.5, 0.8)
163
58
1.0 (reference)
0.6 (0.4, 0.8)
82
32
1.0 (reference)
0.6 (0.4, 1.0)
81
26
1.0 (reference)
0.5 (0.3, 0.8)
FSG (mg/dL) <100
100-109
110-125
≥126
205
  53
  22
  37
32.8
67.9
77.8
93.8
1.0 (reference)
1.4 (1.0, 1.9)
1.3 (0.9, 2.0)
1.2 (0.9, 1.8)
142
37
15
27
1.0 (reference)
1.1 (0.8, 1.6)
1.8 (1.2, 2.6)
73
20
9
12
1.0 (reference)
1.2 (1.0, 2.8)
1.7 (1.0, 2.8)
69
17
6
15
1.0 (reference)
1.1 (0.7, 1.9)
1.9 (1.1, 3.2)
Genetic polymorphism
rs3802842 AA 60 1.0 (reference) 33 1.0 (reference) 27 1.0 (reference)
AC 124 1.7 (1.2, 2.3) 61 1.5 (1.0, 2.3) 63 2.0 (1.3, 3.1)
CC 37 1.3 (0.8, 2.0) 20 1.3 (0.7, 2.4) 17 1.4 (0.8, 2.6)
rs6983267 GG 53 1.0 (reference) 25 1.0 (reference) 28 1.0 (reference)
GT 102 1.1 (0.8, 1.5) 47 0.8 (0.5, 1.2) 55 1.7 (1.0, 2.7)
TT 66 1.4 (1.0, 2.0) 42 0.9 (0.5, 1.5) 24 2.3 (1.3, 3.9)
rs10795668 AA 22 1.0 (reference) 9 1.0 (reference) 13 1.0 (reference)
AG 99 1.0 (0.6, 1.6) 56 1.4 (0.7, 2.9) 43 0.7 (0.4, 1.3)
GG 100 1.4 (0.8, 2.2) 49 1.9 (0.9, 3.9) 51 1.1 (0.6, 1.9)
RR, relative risk; CI, confidence interval; FSG, fasting serum glucose.
1Age-adjusted rate per 100,000 person years.
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Table 3. Age- and gender-adjusted combined effect of SNP rs3802842 and dysglycemia on the risk of colorectal cancer among subjects 
with SNP data (n=1,369) 
Colorectal cancer Colon cancer Rectal cancer
Case RR (95% CI) Case RR (95% CI) Case RR (95% CI)
Dysglycemia
   No
   No
   Yes
   Yes
rs3802842
AA
AC or CC
AA
AC or CC
51
128
9
33
1.0 (reference) 
1.5 (1.1, 2.1)
1.6 (0.7, 3.4)
3.2 (1.9, 5.5)
29
65
  4
17
1.0 (reference) 
1.3 (0.9, 2.1)
1.3 (0.4, 3.8)
2.5 (1.3, 4.6)
22
67
  5
16
1.0 (reference) 
1.9 (1.2, 3.0)
2.1 (0.7, 5.9)
3.4 (1.8, 6.6)
   p-value for interaction         <0.001             0.007 <0.001
Dysglycemia
   No
   No
   Yes
   Yes
rs6983267
GG
GT or TT
GG
GT or TT
47
132
19
23
1.0 (reference) 
1.4 (1.0, 2.0)
3.4 (2.0, 5.8)
1.8 (1.1, 3.1)
32
62
11
10
1.0 (reference) 
1.0 (0.6, 1.5)
2.8 (1.4, 5.7)
1.1 (0.5, 2.3)
16
73
  8
13
1.0 (reference) 
2.3 (1.3, 4.0)
4.2 (1.8, 9.9)
3.3 (1.6, 7.1)
   p- value for interaction             0.001             0.29 <0.001
Dysglycemia
   No
   No
   Yes
   Yes
rs10795668
AA
AG or GG
AA
AG or GG
20
159
2
40
1.0 (reference) 
1.2 (0.7, 1.9)
3.0 (0.7, 12.8)
2.1 (1.2, 3.6)
  9
85
  0
21
1.0 (reference) 
1.5 (0.7, 3.0)
           0.0
2.5 (1.1, 5.6)
12
77
  2
19
1.0 (reference) 
0.9 (0.5, 1.6)
4.6 (1.0, 20.4)
1.6 (0.8, 3.4)
   p-value for interaction             0.001            0.014   0.05
SNP, single-nucleotide polymorphisms; RR, relative risk; CI, confidence interval.
95% CI, 1.6 to 7.1, respectively). The interaction effect of dys-
glycemia and SNPs was positive, resulted in an elevated risk of 
CRC, but was not statistically significant.
DISCUSSION
In this large prospective cohort study of the Korean population, 
we found that high FSG and SNPs rs3802842 and rs6983267 
were independent risk factors for CRC, colon, and rectal can-
cer. No interaction between these risk factors was observed. 
Hyperglycemia
In particular, we found that hyperglycemia, including IFG, 
was associated with CRC incidence, indicating that pre-diabetic 
status might be related to colorectal carcinogenesis. This finding 
was consistent with those of several previous studies [2,8], al-
though the specific classification and study designs differed be-
tween the studies. In the Framingham Heart Study offspring 
cohort, the incidence of CRC was found to be higher in sub-
jects with IFG. The early exposure to high glucose levels was 
strongly associated with CRC, and the HRs proportionally in-
creased with the length of the exposure to IFG [9]. There are 
many mechanistic hypotheses to account for this association 
between hyperglycemia and CRC, including hyperinsulinemia 
occurring through insulin-like growth factor signaling [10-12], 
chronic inflammation [12,13], delayed bowel transit time [14], 
changes in bile acid [15], and imbalanced microbiota in the 
bowel [16].
Genetic factors
When considering early exposure to risk factors for a disease, 
genetic factors are obvious candidates because exposure begins 
before birth and continues for an entire lifetime. In the present 
study, the incidence of rectal cancer was associated with both 
SNPs rs3802842 and rs6983267 [3]. The underlying mecha-
nism of how these SNPs are associated with the incidence of 
colon cancer is as yet undetermined. The association between 
SNP rs3802842 and CRC has been replicated in at least seven 
previous studies, with consistent positive associations [17]. Also, 
SNP rs6983267 has been replicated in at least 14 previous stud-
ies in Western populations [18]. Both SNPs have been previ-
ously reported in Asian populations but only SNP rs6983267 
was found to be associated with rectal cancer in the present 
study. In contrast, SNP rs10795668 did not show any associa-
tion with CRC, colon, or rectal cancer incidence in our study. 
Previous studies were carried out as genome-wide association 
studies designating CRC as the outcome [19]. These studies 
found an association between CRC and CRC-related SNPs. 
Thus, only CRC in general has been examined, and colon and 
rectal cancer had not yet been studied separately as targets. 
However, in our study the SNPs that were associated with rec-
tal cancer showed less correlation with colon cancer. This find-
ing suggests that future association studies should look sepa-
rately at colon and rectal cancers as well as CRC and progres-
sion. It follows that prediction models for colon and rectal can-
cer should also be developed.
Our study has several potential limitations that arise primari-
ly from the use of data collected as part of routine medical ex-
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aminations. The statistical power of the current study may have 
been too low, since genotyping was performed only in a limited 
sample. In addition, our study cohort was not necessarily repre-
sentative of all Koreans because it included only employed per-
sons and their families. However, follow-up should be almost 
complete because of our use of record linkage with unique per-
sonal identifiers to national databases; thus, any loss to follow-
up is unlikely to have introduced bias.
Our study has analyzed the possibility of a mutual interaction 
of diabetes and genetic factors as a potential predictor of CRC, 
and is of importance to the public health and health promotion 
sectors. Research efforts should continue to analyze the interac-
tions between genetic factors, environmental risk factors, and 
prognostic factors that are associated with CRC. 
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